Table 3. Univariate and multivariate analyses of evaluable efficacy PFS patients (N=26).

Characteristics prior enrollment	n (%)	Univariate analyses		Multivariate analyses P	Univariate analyses		Multivariate analyses P
		Median PFS (95% CI)	P		Median OS (95% CI)	P
PFS, progression-free survival; TNBC, triple-negative breast cancer; HR, hormonal receptor; DFS, disease-free survival; IV, primary metastasis; 95% CI, 95% confidence interval; OS, overall survival from enrollment; NE, not evaluable.
Molecular subtype			0.001	0.014		0.120	0.042
TNBC	8 (30.8)	2.3 (1.2−3.4)			8.0 (0−21.9)
HR+	18 (69.2)	7.0 (2.2−11.8)			NE
Lymph node metastasis after surgery			0.112	0.081		0.715	0.375
No	11 (42.3)	6.4 (0.1−18.4)			NE
Yes	11 (42.3)	3.2 (1.0−5.4)			20.0 (5.5−34.5)
IV	4 (15.4)	5.6 (0.1−14.5)			18.0 (1.9−34.0)
DFS (month)			0.107	0.868		0.022	0.311
≤36	15 (57.7)	4.9 (1.9−7.9)			9.0 (7.2−10.8)
>36	11 (42.3)	8.7 (0.2−20.7)			NE
Endocrine therapy prior enrollment			0.323	0.526		0.021	0.918
No	7 (26.9)	3.2 (2.6−3.7)			7.0 (4.4−9.5)
Yes	19 (73.1)	6.0 (3.0−8.9)			NE
Radiation therapy prior enrollment			0.041	0.057		0.343	0.935
No	10 (38.5)	6.4 (1.6−19.5)			NE
Yes	12 (46.2)	3.0 (1.3−4.6)			8.0 (0−19.3)
IV	4 (15.4)	5.6 (0.2−14.5)			18.0 (12.8−23.2)
Site and No. of metastasis			0.258	0.698		0.062	0.031
1 (Chest wall only)	12 (46.2)	4.9 (0−12.7)			NE
2 (Chest wall and others)	14 (53.8)	4.3 (0−8.7)			8.0 (5.8−10.2)
Line of disease prior enrollment			0.660	0.560		0.720	0.435
≤2	13 (50.0)	6.4 (1.9−10.8)			20 (NE)
>3	13 (50.0)	4.3 (1.1−7.5)			17.0 (4.1−29.9)